ID   MM127
AC   CVCL_2601
SY   MM-127
DR   BioSample; SAMN07624422
DR   cancercelllines; CVCL_2601
DR   CBA; CBA-1344
DR   Cell_Model_Passport; SIDM01356
DR   Cosmic; 873569
DR   Cosmic; 889012
DR   Cosmic; 928705
DR   Cosmic; 2159441
DR   DepMap; ACH-001563
DR   ECACC; 10092314
DR   GEO; GSM78852
DR   GEO; GSM78853
DR   GEO; GSM78854
DR   GEO; GSM78855
DR   GEO; GSM78856
DR   GEO; GSM78857
DR   GEO; GSM162904
DR   GEO; GSM219416
DR   Progenetix; CVCL_2601
DR   Wikidata; Q54906044
RX   PubMed=294576;
RX   PubMed=460945;
RX   PubMed=830403;
RX   PubMed=1697409;
RX   PubMed=9354451;
RX   PubMed=10070891;
RX   PubMed=11930117;
RX   PubMed=15048078;
RX   PubMed=17363583;
RX   PubMed=17516929;
RX   PubMed=22383533;
RX   PubMed=27087056;
CC   Problematic cell line: Possibly misclassified. It is not certain that this cell line originate from a metastatic melanoma. Lacks the expression of three protein markers: S100, HMB-45 and Melan-A commonly found in melanoma cell lines (PubMed=27087056). Has a CTNNB1 mutation not seen in other melanoma cell lines (PubMed=11930117).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Unspecified (PubMed=11930117).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; PubMed=22383533).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): CBA; PubMed=27087056
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 12,13
ST   D16S539: 10,13
ST   D18S51: 15,20
ST   D19S433: 13,14
ST   D21S11: 29
ST   D2S1338: 19,20
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10,11 (CBA)
ST   D7S820: 10,12 (PubMed=27087056)
ST   D8S1179: 14,15
ST   FGA: 19,20
ST   Penta D: 10
ST   Penta E: 5,10
ST   TH01: 8,9
ST   TPOX: 11,12
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
RX   PubMed=294576; DOI=10.3109/00313027909059039;
RA   Muir P.D., Gunz F.W.;
RT   "A cytogenetic study of eight human melanoma cell lines.";
RL   Pathology 11:597-606(1979).
RX   PubMed=460945; DOI=10.3109/00313027909061945;
RA   Pope J.H., Morrison L.E., Moss D.J., Parsons P.G., Dunne R.M.;
RT   "Human malignant melanoma cell lines.";
RL   Pathology 11:191-195(1979).
RX   PubMed=830403;
RA   Goss P.D., Parsons P.G.;
RT   "The effect of hyperthermia and melphalan on survival of human
RT   fibroblast strains and melanoma cell lines.";
RL   Cancer Res. 37:152-156(1977).
RX   PubMed=1697409;
RA   Chenevix-Trench G., Martin N.G., Ellem K.A.O.;
RT   "Gene expression in melanoma cell lines and cultured melanocytes:
RT   correlation between levels of c-src-1, c-myc and p53.";
RL   Oncogene 5:1187-1193(1990).
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
RX   PubMed=10070891; DOI=10.1038/sj.bjc.6690147;
RA   Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.;
RT   "p53 mutations in human cutaneous melanoma correlate with sun exposure
RT   but are not always involved in melanomagenesis.";
RL   Br. J. Cancer 79:921-926(1999).
RX   PubMed=11930117; DOI=10.1097/00008390-200204000-00013;
RA   Pollock P.M., Hayward N.K.;
RT   "Mutations in exon 3 of the beta-catenin gene are rare in melanoma
RT   cell lines.";
RL   Melanoma Res. 12:183-186(2002).
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
RX   PubMed=27087056; DOI=10.1038/srep24569;
RA   Haridas P., McGovern J.A., Kashyap A.S., McElwain D.L.S., Simpson M.J.;
RT   "Standard melanoma-associated markers do not identify the MM127
RT   metastatic melanoma cell line.";
RL   Sci. Rep. 6:24569-24569(2016).